Asthma Week

HomePatientsLung Disease Week at the ATS2015Asthma Week ▶ Clinical Trials
Clinical Trials

Asthma Week

Acoustics

ACOUSTICS is a Phase III study evaluating the efficacy, safety and tolerability of lebrikizumab in adolescent patients with asthma whose disease remains uncontrolled despite guideline-based asthma therapy. Click here for more information.

CLAVIER

CLAVIER is a Phase II bronchoscopy study evaluating the effects of lebrikizumab on airway eosinophilic inflammation in patients with asthma whose disease remains uncontrolled despite guideline-based asthma therapy. Click here for more information.

Expect

The Xolair Pregnancy Registry (EXPECT) is an observational study established by Genentech to obtain data on pregnancy outcomes in women who are exposed to Xolair (omalizumab) during their pregnancy. Click here for more information.

Lavolta

LAVOLTA I and LAVOLTA II are two parallel Phase 3 studies designed to evaluate the efficacy and safety of lebrikizumab in patients with uncontrolled asthma despite treatment with guideline-based asthma therapy. Click here for more information.

Prospero

The PROSPERO registry (NCT01922037) is a prospective, observational study designed to examine baseline patient characteristics, including biomarkers, and evaluate predictors of response to omalizumab treatment in patients with allergic asthma. Click here for more information.

Pearl

PT008001 is a clinical research study for adults with mild to moderate persistent asthma. The study will enroll approximately 150 individuals with Asthma in at approximately 45 study centers throughout the United States. Click here for more information.

Stretto

STRETTO is a Phase III study assessing the efficacy and safety of lebrikizumab in adult patients with mild to moderate asthma treated with short-acting beta-agonist therapy alone. Click here for more information.

VOCALS

VOCALS is a Phase II study evaluating the efficacy of lebrikizumab as measured by the ability to achieve lower daily doses of oral corticosteroids in patients with severe corticosteroid-dependent asthma. Click here for more information.